RxDoctor Payments DataLook up a doctor →

James Bowen, MD

Neurology · Kirkland, WANPI 1124072434

Payments from drug & device makers

$2,270,268in general payments, 2019–2025

Across 606 payments — averaging $3746.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$840K
  • Biogen$398K
  • AbbVie$308K
  • Alkermes, Inc.$225K
  • Novartis$127K
  • Roche Products Limited$122K
  • plus $250K from 11 others

What the payments were for

  • Consulting fees$72,99219%
  • Speaking & faculty fees$244,69965%
  • Grants$27,0007%
  • Travel & lodging$25,2227%
  • Food & beverage$9,0372%
  • Education$310%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,270,268 in reported general payments places this provider in the 95th percentile of 418 neurology providers in Washington.

See all neurology providers in Washington

Medicare billing

Part B allowed, 2024
$35,539
Medicare patients
161
Services billed
264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CopaxoneGlatiramer Acetate65$456,047
FingolimodFingolimod Hcl144$436,149
GilenyaFingolimod Hcl28$390,581
Avonex (4 Pack)Interferon Beta-1a34$363,485
RebifInterferon Beta-1a/Albumin23$273,193
TecfideraDimethyl Fumarate27$237,835
Avonex Pen (4 Pack)Interferon Beta-1a15$188,239
Glatiramer Acetate70$171,917
VumerityDiroximel Fumarate16$127,914
Dimethyl Fumarate77$54,591
Dalfampridine ErDalfampridine91$41,211
GlatopaGlatiramer Acetate12$31,344
Baclofen192$7,321
Modafinil104$7,259
Gabapentin161$5,285

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenAvonex (4 Pack), Tecfidera, Vumerity$398,054$729,23377 claims
NovartisGilenya$126,529$390,58128 claims
EMD Serono, Inc.Rebif$8,286$273,19323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 418 neurology providers in Washington.

Other neurology in Kirkland

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →